Publications by authors named "A Fagiolini"
Drugs generally used in major depressive disorder are considered inappropriate for the more common milder forms. The efficacy of saffron extracts has been demonstrated in mild to moderate depression and in preclinical models of depression. However, evidence of saffron activity on reduced hedonic responsiveness and motivational anhedonia is limited.
View Article and Find Full Text PDFBrain-derived neurotrophic factor (BDNF) is critical for neuroplasticity, synaptic transmission, and neuronal survival. Studies have implicated it in the pathophysiology of depression, as its expression is significantly reduced in brain areas such as the prefrontal cortex and hippocampus in patients with depression. Our narrative review focuses on the relationship between BDNF, ketamine, and esketamine, specifically by summarizing human studies investigating BDNF variations in patients treated with these two drugs.
View Article and Find Full Text PDFArticle Synopsis
- * PMA occurs in 4.3% to 10% of psychiatric emergencies, creating a heavy burden on healthcare systems, yet there’s a gap in standardized treatment protocols, especially regarding the use of liquid antipsychotics like liquid promazine.
- * The review analyzes the benefits of liquid promazine, which include ease of use, quick action, and better patient adherence, but emphasizes the need for further research to validate its effectiveness compared to other antips
Background: In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release.
Aims: To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release.
Method: ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial.